protein

Tau

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Tau: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

5625Connections

30Hypotheses

30Analyses

50Outgoing

50Incoming

No summary available yet. View on Wiki →

🔬 Protein Info

Gene Symbol	TAU
Chromosome	17q21.31
Protein Family	MAPT family
Function	is an important component in the neurobiology of neurodegenerative diseases.
Primary Expression	neurons, where they bind to microtubules and promote their polymerization and stability
Subcellular Localization	Axons, Neurons
Molecular Weight	45-65 kDa (isoform dependent)
Amino Acids	441 aa
Pathways	Extracellular Aggregation, Hyperphosphorylation, Neurofibrillary Tangle Formation, Protein Assembly, Synapse Pathology
GeneCards	TAU
Human Protein Atlas	TAU
Associated Diseases	Alzheimer'S Disease, Cognitive Decline, Detergent Extraction Resistance, Glial Lipid Accumulation
Known Drugs/Compounds	Tau Immunotherapies, Tau-Targeting Therapies
Interactions	nucleoporin, ARHGEF2, HSPG2, STROKE, GABA, CD33
KG Connections	164 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (20)

Knowledge base pages for this entity

cbs-psp-daily-action-plan

therapeutic · 30834 words

→

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

→

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

therapeutic · 15567 words

→

Clinical Management Guide for CBS/PSP

therapeutic · 15224 words

→

Progressive Supranuclear Palsy (PSP)

disease · 12907 words

→

Pathway Diagram

graph TD
    Tau["Tau"] -->|"modulates"| Microtubule_Labile_Domain["Microtubule Labile Domain"]
    style Microtubule_Labile_Domain fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    Tau["Tau"] -->|"causes"| Alzheimer_s_Disease["Alzheimer's Disease"]
    style Alzheimer_s_Disease fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    Tau["Tau"] -->|"biomarker for"| Frontotemporal_Degeneration["Frontotemporal Degeneration"]
    style Frontotemporal_Degeneration fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    Tau["Tau"] -->|"biomarker for"| Alzheimer_Disease["Alzheimer Disease"]
    style Alzheimer_Disease fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    Tau["Tau"] -->|"mediates"| Nigrostriatal_Dopaminergic_Neu["Nigrostriatal Dopaminergic Neurodegeneration"]
    style Nigrostriatal_Dopaminergic_Neu fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    Tau["Tau"] -->|"biomarker for"| Frontotemporal_Dementia["Frontotemporal Dementia"]
    style Frontotemporal_Dementia fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    Tau["Tau"] -->|"regulates"| Neuronal_Development["Neuronal Development"]
    style Neuronal_Development fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    TRIAD3A["TRIAD3A"] -->|"associated"| Tau["Tau"]
    style TRIAD3A fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    Tau_Targeting_Therapies["Tau-Targeting Therapies"] -->|"targets"| Tau["Tau"]
    style Tau_Targeting_Therapies fill:#1a2a3a,stroke:#81c784,stroke-width:1px,color:#fff
    Protein_Aggregation["Protein Aggregation"] -->|"involved in"| Tau["Tau"]
    style Protein_Aggregation fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    Tau_Immunotherapies["Tau Immunotherapies"] -->|"targets"| Tau["Tau"]
    style Tau_Immunotherapies fill:#1a2a3a,stroke:#81c784,stroke-width:1px,color:#fff
    SIRT1["SIRT1"] -->|"associated"| Tau["Tau"]
    style SIRT1 fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    style Tau fill:#006494,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold

Outgoing (3032)

Target	Relation	Type	Str
Microtubule Labile Domain	modulates	process	0.95
Alzheimer's Disease	causes	disease	0.95
Alzheimer's Disease	biomarker_for	disease	0.95
Frontotemporal Degeneration	biomarker_for	disease	0.95
Microtubule Labile Domain	associated_with	process	0.95
Nigrostriatal Dopaminergic Neurodegeneration	mediates	process	0.95
Frontotemporal Dementia	biomarker_for	disease	0.95
Alzheimer'S Disease	contributes_to	disease	0.95
Alzheimer'S Disease	causes	disease	0.95
Apoptosis	associated_with	process	0.95
Alzheimer'S Disease	associated_with	disease	0.95
Neurofibrillary Tangles	involved_in	phenotype	0.95
Neurofibrillary Tangles	contributes_to	biomarker	0.95
Neuronal Development	regulates	process	0.92
Microtubules	interacts_with	compound	0.90
Microtubules	binds	process	0.90
Phosphorylation	involved_in	process	0.90
Neurodegeneration	causes	process	0.90
Growth Cone Turning	modulates	process	0.88
Axon Microtubule Organization	regulates	process	0.85
Microtubule Dynamics	regulates	process	0.85
Axonal Microtubules	expressed_in	cell_type	0.85
Neuronal Migration	regulates	process	0.85
Axonal Branching	modulates	process	0.85
Cytoplasmic DNA Release	causes	process	0.85
Neurodegeneration	involved_in	process	0.85
Mitochondrial Stress	associated_with	process	0.85
Intercellular Propagation	involved_in	process	0.85
Donanemab Efficacy	modulates	phenotype	0.85
MAP6	associated_with	protein	0.80
Detergent Extraction Resistance	associated_with	phenotype	0.80
Synaptic Processes	associated_with	biological_process	0.80
Mitochondrial Processes	associated_with	biological_process	0.80
Neurodegeneration	associated_with	disease	0.80
Mitochondrial dysfunction	causes	phenotype	0.80
Microglia	activates	cell_type	0.80
Cognitive Decline	causes	phenotype	0.80
Alzheimer's disease	causes	disease	0.70
MAPT	interacts_with	entity	0.70
MAPT	associated_with	entity	0.70
Microglia	interacts_with	cell_type	0.70
Chronic Cerebral Hypoperfusion	involved_in	process	0.70
Glial Lipid Accumulation	associated_with	phenotype	0.70
microtubule	interacts_with	process	0.70
nucleoporin	interacts_with	protein	0.70
translational stress response	modulates	process	0.70
Aβ-driven toxicity	contributes_to	phenotype	0.60
Alzheimer's disease	implicated_in	disease	0.60
alpha-synuclein	co_expressed_with	protein	0.60
neuronal ADORA1	regulates	protein	0.60

Incoming (2593)

Source	Relation	Type	Str
TRIAD3A	associated_with	protein	0.95
Tau-Targeting Therapies	targets	drug	0.95
GSK-3β	phosphorylates	protein	0.95
Protein Aggregation	involved_in	process	0.90
Tau Immunotherapies	targets	drug	0.90
APOE	interacts_with	gene	0.90
Cabergoline	downregulates	drug	0.90
SGK1	phosphorylates	gene	0.85
SIRT1	associated_with	protein	0.80
Qingxin Kaiqiao Fang	associated_with	drug	0.80
APOE	associated_with	gene	0.80
Amyloid Beta	associated_with	protein	0.80
Microglia	interacts_with	cell_type	0.80
Astrocytes	interacts_with	cell_type	0.80
GLP-1	ameliorates	protein	0.80
autophagy	activates	process	0.70
autophagy	regulates	process	0.70
MAPT	activates	entity	0.70
MAPT	interacts_with	entity	0.70
MAPT	associated_with	entity	0.70
GSK3β	regulates	protein	0.70
mitochondrial dysfunction	activates	process	0.70
cellular energy deficit	activates	process	0.70
ARHGEF2	interacts_with	gene	0.70
IQCK	associated_with	gene	0.70
Amyloid-β	associated_with	protein	0.70
Amyloid-β	mediates	protein	0.70
Chronic Cerebral Hypoperfusion	regulates	condition	0.70
MAPT	encodes	gene	0.60
AXON	expressed_in	gene	0.60
PHAGOCYTOSIS	protects_against	gene	0.60
JUN	protects_against	gene	0.60
RELN	protects_against	gene	0.60
REELIN	protects_against	gene	0.60
HSPG2	interacts_with	gene	0.60
STROKE	activates	gene	0.60
GABA	interacts_with	gene	0.60
P21	regulates	gene	0.60
TERT	regulates	gene	0.60
TERC	regulates	gene	0.60
P16	regulates	gene	0.60
IL-6	regulates	gene	0.60
IRF4	therapeutic_target	gene	0.60
SOD1	therapeutic_target	gene	0.60
GRN	therapeutic_target	gene	0.60
FUS	therapeutic_target	gene	0.60
C9ORF72	therapeutic_target	gene	0.60
MET	therapeutic_target	gene	0.60
NPTX2	regulates	gene	0.60
TAUOPATHY	expressed_in	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Closed-loop tACS targeting EC-II SST interneurons to block t	0.697	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop focused ultrasound targeting EC-II SST interneur	0.697	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II PV interneurons to suppress	0.670	Alzheimer's disease	Circuit-level neural dynamics in neurode
Beta-frequency entrainment therapy targeting PV interneuron-	0.669	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II parvalbumin interneurons to	0.660	Alzheimer's disease	Circuit-level neural dynamics in neurode

Closed-loop tACS targeting entorhinal cortex layer II SST in	0.625	Alzheimer's disease	Circuit-level neural dynamics in neurode
Closed-loop transcranial focused ultrasound targeting EC-II	0.612	Alzheimer's disease	Circuit-level neural dynamics in neurode
DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxici	0.609	neurodegeneration	Should microtubule-stabilizing drugs be
GPC4/HSPGs Collaborate with ApoE Isoforms to Dictate Tau Con	0.583	neurodegeneration	What are the specific molecular determin
DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against T	0.579	neurodegeneration	Should microtubule-stabilizing drugs be
Closed-loop tACS targeting EC-II PV interneurons to enhance	0.578	Alzheimer's disease	Circuit-level neural dynamics in neurode
GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl	0.575	neuroscience	Circuit-level neural dynamics in neurode
Closed-loop focused ultrasound targeting EC-II PV interneuro	0.568	Alzheimer's disease	Circuit-level neural dynamics in neurode
Glymphatic-Mediated Tau Clearance Dysfunction	0.546	neuroscience	Circuit-level neural dynamics in neurode
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Sign	0.533	neuroscience	Circuit-level neural dynamics in neurode
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular	0.527	neuroscience	Circuit-level neural dynamics in neurode
Noradrenergic-Tau Propagation Blockade	0.510	neurodegeneration	Sleep disruption as cause and consequenc
Closed-loop transcranial focused ultrasound targeting CA1 PV	0.508	Alzheimer's disease	Circuit-level neural dynamics in neurode
Selective Tau Kinase Inhibition in Vulnerable Neuronal Subty	0.504	neurodegeneration	Cell type vulnerability in Alzheimers Di
Dual-Circuit Tau Vulnerability Cascade	0.499	neuroscience	Circuit-level neural dynamics in neurode
CYP46A1 Suppression for Tau-Mediated Neurodegeneration	0.494	neurodegeneration	Lipid raft composition changes in synapt
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece	0.489	neuroscience	Circuit-level neural dynamics in neurode
TREM2-mediated microglial tau clearance enhancement	0.487	Alzheimer's Disease	Tau propagation mechanisms and therapeut
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme	0.480	neurodegeneration	Selective vulnerability of entorhinal co
Microglial Exosome-Mediated Tau Propagation	0.468	neuroscience	Circuit-level neural dynamics in neurode
Dual-Circuit Tau Vulnerability Cascade with Glial-Mediated A	0.461	neuroscience	Circuit-level neural dynamics in neurode
HDAC6 Inhibition for Dual Restoration of Microtubule Stabili	0.459	neurodegeneration	Which tau PTMs are both disease-specific
Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in	0.456	Alzheimer's disease	TREM2 agonism vs antagonism in DAM micro
TREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocy	0.452	neuroscience	Circuit-level neural dynamics in neurode
TREM2-Dependent Microglial Surveillance Controls AQP4-Mediat	0.452	neuroscience	Circuit-level neural dynamics in neurode

Mentioning Analyses (30)

Scientific analyses that reference this entity

What are the specific molecular determinants that govern tau strain selection du

neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.583

Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.609

Why does PRKN-mediated mitophagy, typically protective, cause harmful mitochondr

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.455

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t

neurodegeneration | 2026-04-15 | 0 hypotheses

Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.604

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Gray matter structural and molecular signatures in Alzheimer's disease and late- [PMID:41419068]	Yang S, Wang X, Yan Y, Zhang J, Wei Y et	J Affect Disord	2026
Duloxetine Improves Early Clinical Outcomes Including Range of Motion, Functiona [PMID:41934361]	Han SC, Han J, Min YK, Han JW, Jeong HJ	Am J Sports Med	2026
External fixation versus reverse shoulder arthroplasty for proximal humerus frac [PMID:41940987]	Vadalà A, Benelli C, Suraci F, Carta B,	Arch Orthop Trauma Surg	2026
Modeling and simulation of conducting airways during continuous high-frequency o [PMID:41941967]	Huang X, Francis I, Gu Y, Saha SC	Respir Physiol Neurobiol	2026
Potential antidepressant properties of aminophylline in male mice exposed to chr [PMID:41945313]	Samante FI, Galangue CG, Avelino DC, Bel	Pharmacol Rep	2026
Robot-assisted immediate implant placement with the socket shield technique in t [PMID:41963213]	Wu J, Lin B, Yang S, Xu S, Li S	J Prosthet Dent	2026
Fate plasticity of interneuron specification. [PMID:40264797]	Mostajo-Radji MA, Leon WRM, Breevoort A,	iScience	2025
Human stem cell-derived GABAergic interneuron development reveals early emergenc [PMID:40651475]	Bershteyn M, Zhou H, Fuentealba L, Chen	Neuron	2025
Forebrain assembloids support the development of fast-spiking human PVALB+ corti [PMID:40695284]	Walsh RM, Crabtree GW, Kalpana K, Jubier	Neuron	2025
Anterior cingulate cortex parvalbumin and somatostatin interneurons shape social [PMID:40320404]	Qi C, Sima W, Mao H, Hu E, Ge J et al.	Nat Commun	2025
Distinct dendritic integration strategies control dynamics of inhibition in the [PMID:40592329]	Morabito A, Zerlaut Y, Dhanasobhon D, Be	Neuron	2025
Targeting SARM1 improves autophagic stress-induced axonal neuropathy. [PMID:37561040]	Kim HR, Lee HJ, Jeon Y, Jang SY, Shin YK	Autophagy	2024
Integrated multimodal cell atlas of Alzheimer's disease. [PMID:39402379]	Gabitto MI, Travaglini KJ, Rachleff VM,	Nat Neurosci	2024
Identification of early Alzheimer's disease subclass and signature genes based o [PMID:39650656]	Wang W, Lu J, Pan N, Zhang H, Dai J et a	Front Immunol	2024
Cortical assembloids support the development of fast-spiking human PVALB+ cortic [PMID:39651135]	Walsh RM, Crabtree GW, Kalpana K, Jubier	bioRxiv	2024
Cortical somatostatin long-range projection neurons and interneurons exhibit div [PMID:38086373]	Fisher J, Verhagen M, Long Z, Moissidis	Neuron	2024
Locus Coeruleus-Dorsolateral Septum Projections Modulate Depression-Like Behavio [PMID:38155473]	Zhang Q, Xue Y, Wei K, Wang H, Ma Y et a	Adv Sci (Weinh)	2024
Somatostatin and the pathophysiology of Alzheimer's disease. [PMID:38484981]	Almeida VN	Ageing Res Rev	2024
Somatostatin interneurons control the timing of developmental desynchronization [PMID:38599213]	Mòdol L, Moissidis M, Selten M, Oozeer F	Neuron	2024
De novo gene synthesis by an antiviral reverse transcriptase. [PMID:39116258]	Tang S, Conte V, Zhang DJ, Žedaveinytė R	Science	2024

Tau

Understanding Entity Pages

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Parkinson's Disease

Sleep and Circadian Dysfunction in Alzheimer's Disease

Microglia CD8+ T Cell Recruitment -- Supplementary WW Content

primary-progressive-aphasia

CBS/PSP Supplements Guide

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

Parthanatos in Neurodegeneration

CBS/PSP Rehabilitation Master Guide

calcium-dysregulation-comparison

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Alpha-Synuclein Pathology

Myoclonus and Cortical Hyperexcitability in Corticobasal Syndrome

Pathway Diagram

Outgoing (3032)

Incoming (2593)

Targeting Hypotheses (30)

Mentioning Analyses (30)

What are the specific molecular determinants that govern tau strain selection du

Should microtubule-stabilizing drugs be reconsidered as therapeutic targets for

Why does PRKN-mediated mitophagy, typically protective, cause harmful mitochondr

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t

Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI

What molecular mechanisms underlie the dose-dependent protective effects of the

Which tau PTMs are both disease-specific and druggable with selective small mole

What is the atomic-resolution structure of K280-acetylated tau and how does it t

Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD

Extracellular vesicle biomarkers for early AD detection

Do tau aggregates represent protective responses or primary pathogenic drivers i

Do P2RX7 antagonists selectively block pathogenic exosomes while preserving bene

Does tau aggregation specifically cause PS externalization in vesicles independe

Does tau aggregation specifically cause PS externalization in living cells versu

Which specific post-translational modifications create druggable epitopes unique

Which specific post-translational modifications distinguish pathological from ph

Do tau-specific HSP90 conformational states exist that differ from other client

What evidence supports Cdk5 activation as THE primary cause of AD versus other e

Do tau strains or regional cellular environments primarily drive PSP vs CBD path

Which specific post-translational modifications on pathological tau create drugg

Do tau-containing vesicles exhibit unique surface glycosylation patterns that di

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

What determines the selectivity and efficiency of intercellular transmission pat

How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting

Which tau propagation mechanism predominates in different brain regions and dise

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

What is the therapeutic window between tau propagation inhibition and essential

Lysosomal dysfunction and cathepsin leakage in Alzheimer disease progression

Trans-synaptic tau spreading and propagation mechanisms in AD

Investigate prion-like spreading of tau pathology through connected brain region

Related Papers (20)